Advancing inclusive research (AIR) site alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical research.

Diversity Health equity Inclusive research Oncology Ophthalmology Study site

Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
16 Dec 2023
Historique:
received: 24 08 2023
revised: 11 12 2023
accepted: 15 12 2023
medline: 19 12 2023
pubmed: 19 12 2023
entrez: 18 12 2023
Statut: aheadofprint

Résumé

The Advancing Inclusive Research (AIR) Site Alliance is composed of clinical research centers that partner with Genentech, a biotechnology company, to advance the representation of diverse patient populations in its oncology and ophthalmology clinical trials, test recruitment, and retention approaches and establish best practices to leverage across the industry to achieve health equity. Through a data-driven selection process, Genentech identified 6 oncology and 3 ophthalmology partners that focus on reaching historically underrepresented patients in clinical trials and worked collaboratively to share knowledge and explore original ways of increasing clinical study access for every patient, including sites co-creation of a Protocol Entry Criteria Guideline with inclusion principles. For patients, three publicly available educational videos about clinical trials were created in multiple languages. The AIR Site Alliance has also defined invoiceable services for sites to enhance patient support; this has been built into the new study budget templates for sustainability. For healthcare professionals (HCPs), the first-of-its-kind AIR Educational Program was developed to focus on identifying and addressing bias and engaging historically underrepresented patient populations in trials. The sites also co-created videos for HCPs and patients on why advancing inclusive research matters. Over 16 regional health equity symposia have been delivered for patients, HCPs, and community leaders. This AIR Site Alliance is a model for other site alliances, including Kenya, South Africa, the United Kingdom, and Canada. Such alliances will build a robust and sustainable research ecosystem that includes diverse patient groups and encourages change across the healthcare system.

Sections du résumé

BACKGROUND BACKGROUND
The Advancing Inclusive Research (AIR) Site Alliance is composed of clinical research centers that partner with Genentech, a biotechnology company, to advance the representation of diverse patient populations in its oncology and ophthalmology clinical trials, test recruitment, and retention approaches and establish best practices to leverage across the industry to achieve health equity.
METHODS METHODS
Through a data-driven selection process, Genentech identified 6 oncology and 3 ophthalmology partners that focus on reaching historically underrepresented patients in clinical trials and worked collaboratively to share knowledge and explore original ways of increasing clinical study access for every patient, including sites co-creation of a Protocol Entry Criteria Guideline with inclusion principles.
RESULTS RESULTS
For patients, three publicly available educational videos about clinical trials were created in multiple languages. The AIR Site Alliance has also defined invoiceable services for sites to enhance patient support; this has been built into the new study budget templates for sustainability. For healthcare professionals (HCPs), the first-of-its-kind AIR Educational Program was developed to focus on identifying and addressing bias and engaging historically underrepresented patient populations in trials. The sites also co-created videos for HCPs and patients on why advancing inclusive research matters. Over 16 regional health equity symposia have been delivered for patients, HCPs, and community leaders.
CONCLUSIONS CONCLUSIONS
This AIR Site Alliance is a model for other site alliances, including Kenya, South Africa, the United Kingdom, and Canada. Such alliances will build a robust and sustainable research ecosystem that includes diverse patient groups and encourages change across the healthcare system.

Identifiants

pubmed: 38109966
pii: S1551-7144(23)00339-7
doi: 10.1016/j.cct.2023.107416
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107416

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Gregory A Vidal (GA)

West Cancer Center & Research Institute, Germantown, TN, USA. Electronic address: gvidal@WESTCLINIC.com.

Patricia Chalela (P)

Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.

Andrea N Curry (AN)

West Cancer Center & Research Institute, Germantown, TN, USA.

Bassel El-Rayes (B)

O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL, USA.

Balazs Halmos (B)

Montefiore Einstein Cancer Center, Bronx, NY, USA.

Alex F Herrera (AF)

City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Kapil G Kapoor (KG)

Wagner Kapoor Institute, Norfolk, VA, USA.

Supreet Kaur (S)

Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.

Daruka Mahadevan (D)

Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.

Ruben Mesa (R)

Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.

Amelie Ramirez (A)

Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.

Barry Sleckman (B)

O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL, USA.

Alan L Wagner (AL)

Wagner Kapoor Institute, Norfolk, VA, USA.

Ruma Bhagat (R)

Genentech, Inc., South San Francisco, CA, USA.

Isabel Brown (I)

Genentech, Inc., South San Francisco, CA, USA.

Leia Cruz (L)

Genentech, Inc., South San Francisco, CA, USA.

Audrey Funwie (A)

Genentech, Inc., South San Francisco, CA, USA.

Quita Highsmith (Q)

Genentech, Inc., South San Francisco, CA, USA.

Nicole Richie (N)

Genentech, Inc., South San Francisco, CA, USA.

Meghan McKenzie (M)

Genentech, Inc., South San Francisco, CA, USA.

Classifications MeSH